Sidley represented ADVANZ PHARMA, a Nordic Capital portfolio company, in connection with the issuance of €917 million (equivalent) in new euro- and pound sterling-denominated senior secured notes and the borrowing of a €165 million term loan B facility, the proceeds of which were used primarily to redeem in full ADVANZ PHARMA’s existing senior secured notes.
ADVANZ PHARMA is a global pharmaceutical company with a focus on providing access to high quality specialty, hospital, and rare disease medicines. Its product portfolio spans over 15 therapeutic areas and supports commercial sales in over 90 countries.
The Sidley team was led by partners Scott Colwell and Patrick Kwak (Capital Markets) and Sam Hamilton and Joseph Kimberling (Global Finance). They were supported by Johanna Selberg and Tosh Scheps (Capital Markets); and Chris Devine and Raphael Chow (Global Finance). The broader cross-office and cross-practice team included Dr. Markus Feil, Dr. Christoph Jensen, and Alissia Opitz (Global Finance); Beth Dickstein (Employee Benefits and Executive Compensation); Carla Teodoro and John Ekblad (Investment Funds); Nicholas Brown, Ryan Kelly, and Michael Sliskovich (U.S. Tax); Kieran Sharma and Hannah Murray (Restructuring); and Steve Quinn and Patrick Graham (U.K. Tax).
